RecruitingNCT07421739
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
Sponsor
Aura Biosciences
Enrollment
15 participants
Start Date
Nov 12, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
Eligibility
Inclusion Criteria2
- Have enrolled in the Aura-sponsored clinical trial AU-011-301.
- Access to a connected device (i.e., smartphone, laptop, or tablet)
Exclusion Criteria1
- None
Interventions
OTHERNon-interventional, digital, patient-reported, real-world study
Surveys will be collected at the following key timepoints: Scheduled visits: Visit 2\_Cycle 1\_Day 1 Visit 8 (week 4, Day 29) Visit 19 (24-hr f/y +/- 4hrs last tx) Visit 20 (week 12, day 84) Visit 22 (week 20, day 84) Visit 25 (week 52, day 364) Visit 26 (week 65, day 455) Visit 27 (week 78, day 546) Visit 28 (week 91, day 637) Visit 29 (week 104, day 728) End of Trial or Early Termination
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07421739
Related Trials
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
NCT073644741 location
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT047924631 location
Adjuvant Tebentafusp in High Risk Ocular Melanoma
NCT0624614914 locations
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT0600769071 locations